A5007057062- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Ferroptosis and cancer prognosis
- Lung Cancer Research Studies
- Cancer-related molecular mechanisms research
- Immunotherapy and Immune Responses
- interferon and immune responses
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Calcium signaling and nucleotide metabolism
- RNA regulation and disease
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- RNA and protein synthesis mechanisms
- MicroRNA in disease regulation
- PI3K/AKT/mTOR signaling in cancer
- Biochemical and Molecular Research
- Adenosine and Purinergic Signaling
- Cancer-related gene regulation
- Advanced biosensing and bioanalysis techniques
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
The University of Texas MD Anderson Cancer Center
2014-2023
Brigham and Women's Hospital
2022
Stanford University
2019
Palo Alto University
2019
National Institutes of Health
2019
Harvard University
2011-2014
Sun Yat-sen University
2014
Yale University
2014
Tongji Hospital
2005
Huazhong University of Science and Technology
2005
Abstract Despite recent advances in the use of immunotherapy, only a minority patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that targeting DNA damage response (DDR) proteins PARP and kinase 1 (CHK1) significantly increased protein surface expression PD-L1. or CHK1 inhibition remarkably potentiated antitumor effect PD-L1 augmented cytotoxic T-cell infiltration multiple immunocompetent SCLC vivo models. CD8+ depletion reversed effect,...
Abstract Although treatment with immune checkpoint inhibitors provides promising benefit for patients cancer, optimal use is encumbered by high resistance rates and requires a thorough understanding of mechanisms. We observed that tumors treated PD-1/PD-L1 blocking antibodies develop through the upregulation CD38, which induced all-trans retinoic acid IFNβ in tumor microenvironment. In vitro vivo studies demonstrate CD38 inhibits CD8+ T-cell function via adenosine receptor signaling or...
Abstract Purpose: Promising results in the treatment of non–small cell lung cancer (NSCLC) have been seen with agents targeting immune checkpoints, such as programmed death 1 (PD-1) or ligand-1 (PD-L1). However, only a select group patients respond to these interventions. The identification biomarkers that predict clinical benefit checkpoint blockade is critical successful translation agents. Methods: We conducted an integrated analysis three independent large datasets, including Cancer...
Abstract Tumor extracellular matrix has been associated with drug resistance and immune suppression. Here, proteomic RNA profiling reveal increased collagen levels in lung tumors resistant to PD-1/PD-L1 blockade. Additionally, elevated correlates decreased total CD8 + T cells exhausted cell subpopulations murine human tumors. Collagen-induced exhaustion occurs through the receptor LAIR1, which is upregulated following CD18 interaction collagen, induces SHP-1. Reduction tumor deposition LOXL2...
// Limo Chen 1,* , Bertal H Aktas 1,2,* Yibo Wang 1 Xiaoying He 1,3 Rupam Sahoo Nancy Zhang Severine Denoyelle Eihab Kabha Hongwei Yang Revital Yefidoff Freedman Jeffrey G Supko Michael Chorev 1,2 Gerhard Wagner and Jose A Halperin Harvard Medical School 2 Brigham Women's Hospital 3 Massachusetts General * These authors are equal contributors Correspondence: A. email: Keywords : Translation, eIF4F, eIF4E, ternary complex, eIF2 Received August 09, 2012, Accepted 24, Published 25, 2012...
Abstract Understanding resistance mechanisms to targeted therapies and immune checkpoint blockade in mutant KRAS lung cancers is critical developing novel combination improving patient survival. Here, we show that MEK inhibition enhanced PD-L1 expression while upregulated MAPK signaling tumors. Combined with anti-PD-L1 synergistically reduced tumor growth metastasis, but tumors eventually developed sustained combinatorial therapy. Multi-platform profiling revealed resistant have increased...
ABSTRACT The UVB (290–320 nm) radiation in sunlight is responsible for inducing skin cancer. Exposure to UV also immunosuppressive, and the systemic immune suppression induced by a well-recognized risk factor cancer induction. As absorbed within upper layers of skin, indirect mechanisms must play role activating suppression. One prominent example mast cell migration, which from draining LN an essential step cascade events leading What triggers migration not entirely clear. Here, we tested...
// Mei-Ting Qiu 1, * , Qiong Fan Zhu 2, Suet-Ying Kwan 2 Limo Chen 3 Jin-Hong 4 Zuo-Lin Ying 5 Ye Zhou 1 Wei Gu Li-Hua Wang Wei-Wei Cheng Jianfang Zeng 6 Xiao-Ping Wan Samuel C. Mok Kwong-Kwok Wong Bao Departments of Obstetrics and Gynecology, International Peace Maternity & Child Health Hospital affiliated with the Shanghai Jiao Tong University School Medicine, Shanghai, China Department Gynecologic Oncology Reproductive The Texas MD Anderson Cancer Center, Houston, TX, USA Thoracic/Head...
Epithelial–mesenchymal transition and immunosuppression are crucial for cancer metastasis treatment resistance. The mechanism by which these distinct processes co-opted remains incompletely understood. Our recent work has exposed the "dirty affairs" of 2 at tumor site, thus calling a combined therapy to break such dangerous liaison.
The 4EGI-1 is the prototypic inhibitor of eIF4E/eIF4G interaction, a potent translation initiation in vitro and vivo an efficacious anticancer agent animal models human cancers. We report on design, synthesis, characterization series rigidified mimetic this which phenyl 2-(4-(3,4-dichlorophenyl)thiazol-2-yl) moiety was bridged into tricyclic system. bridge consisted one following: ethylene, methylene oxide, methylenesulfide, methylenesulfoxide, methylenesulfone. Numerous analogues were found...
Cancer cells modulate the recruitment and function of inflammatory to create an immunosuppressive microenvironment that favors tumor growth metastasis. However, tumor-derived regulatory programs promote intratumoral immunosuppression remain poorly defined. Here, we show in a KrasLA1/+p53R172HΔg/+-based mouse model bone morphogenetic protein-4 (BMP4) augments expression T cell co-inhibitory receptor ligand PD-L1 mesenchymal subset lung cancer cells, leading profound CD8+ cell-mediated...
CXCL14 is a relatively new chemokine with unidentified receptor and undefined function. Recently, we found that upregulated in arthritic joints mouse model of autoimmune arthritis, collagen-induced arthritis. To examine the role development pathogenesis have generated transgenic (Tg) mice overexpress under control phosphoglycerate kinase promoter. The results showed CXCL14-Tg developed more severe arthritis compared wild-type controls. draining lymph nodes were significantly enlarged...
Introduction Despite significant clinical advancement with the use of immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) there are still a major subset patients that develop adaptive/acquired resistance. Understanding resistance mechanisms to ICB is critical developing new therapeutic strategies and improving patient survival. The dynamic nature tumor microenvironment mutational load driving immunogenicity limit efficacy ICB. Recent studies indicate myeloid cells drivers...
AIM:To investigate the in vitro antitumor effect of adenovirus-mediated small interfering RNAs (siRNAs) on pancreatic cancer and associated mechanism. METHODS:A 63-nucleotide (nt) oligonucleotide encoding K-ras val12 specific siRNA were introduced into pSilencer 3.1-H1, then H1-RNA promoter coding insert subcloned pAdTrack to get plasmid pAdTrackH1-K-ras .After homologous recombination bacteria transfections such plasmids a mammalian packaging cell line 293, expressing adenovirus AdH1-K-ras...
79 Background: Although immune checkpoint inhibitors including PD-L1 blockade provide significant clinical benefit for patients with lung cancer, barriers to immunotherapy successes have been due a high rate of resistance. The therapeutic improvement requires thorough understanding the biological process Until recently, there only few studies reporting mechanisms resistance blockade. mechanistic basis remains poorly defined. Methods: In multiple immunocompetent syngeneic and...
Abstract 4EGI‐1, the prototypic inhibitor of eIF4E/eIF4G interaction, was identified in a high‐throughput screening small‐molecule libraries with aid fluorescence polarization assay that measures inhibition binding an eIF4G‐derived peptide to recombinant eIF4E. As such, molecular probe 4EGI‐1 has potential for study mechanisms involved human disorders characterized by loss physiological restraints on translation initiation. A hit‐to‐lead optimization campaign carried out overcome...
Mucin1 (MUC1) promoter has been cloned from the 5' flanking region of MUC1 gene in breast carcinoma, functionally characterized and applied therapy esophageal carcinoma. In present study, we amplified a 786 base pair (bp) by two-step nest PCR, identified activity tumor-specificity using an enhanced green fluorescent protein (EGFP) as reporter fluorescence microscopy flow cytometry analysis Panc-1, primary normal pancreatic (PNPC), cervical cancer HeLa cell lines. Subsequently, human...
144 Background: The combination of anti-PD-1 and anti-CTLA-4 is a promising strategy that being clinically explored to treat variety cancer types. Some patients display primary resistance this treatment, while others relapse after treatment. Although some have long-term durable responses the therapy anti-CTLA-4, physicians been looking for biomarkers predict response. Methods: Using multiple immunocompetent syngeneic K-rasLA1/+p53R172H?g/+ spontaneous animal models lung cancer, we mechanisms...